SOLESENCE, INC. (SLSN): Entry into a Material Definitive Agreement
SOLESENCE, INC. (SLSN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 DATED: 6 July 2026 (1) REFY BEAUTY LTD (2) SOLÉSENCE LLC Settlement agreement and release CONTENTS 1. Definitions and Interpretation 3 2. EFFECT of this agreement 4 3. Payment 4 4. EXCLUSIVITY 5 5. RELEASE 6 6. agreement not to sue
How this was made
The 30-second read
Why it matters
The agreement sets a total settlement sum of £700,000, payable in USD at a stated exchange rate, with installment deadlines from Aug 2026 through Jan 2027 (and additional installments through July 2027 if no new SPF commercial contract is entered during the exclusivity period). Payment defaults can accelerate remaining amounts and release REFY from exclusivity obligations.
Market read
This is a concrete legal settlement disclosure with explicit cash payment timing and default consequences, which can affect near-term liquidity risk perception.
What to watch
Traders should focus on whether the exclusivity period and the credit-or-pay structure (credit against a new SPF contract vs. cash payment) changes expected future revenue visibility, not just the headline settlement sum.
Background
The 8-K Item 1.01 reports Solésence’s entry into a settlement agreement resolving a dispute tied to a June 3, 2024 contract manufacturing agreement with REFY.
Ticker impact
Solesence (SLSN) entered a material settlement agreement, paying REFY £700,000 with defined installment dates and default triggers.
Likely modest, mostly balance-sheet/cash-flow sensitivity unless the settlement size is large relative to SLSN’s liquidity; acceleration clauses add downside tail risk.
The 8-K discloses a specific £700,000 settlement with scheduled payments through July 2027 and explicit consequences for missed installments, which can affect perceived liquidity and risk. However, the filing excerpt does not provide SLSN’s financial context to gauge materiality for equity repricing.
Market effects
Highlights contract-manufacturing dispute resolution risk in beauty supply chains, potentially affecting how investors price counterpart risk and exclusivity arrangements.
Limited, as the settlement is cross-border (GBP to USD) but tied to a specific bilateral dispute.
Low, primarily company-specific legal and commercial terms rather than a broad industry event.
Counterpoint
If SLSN has sufficient liquidity, the settlement may be viewed as a one-time clean-up with limited ongoing earnings impact, reducing the likelihood of sustained negative repricing.
Key entities
- issuerSOLESENCE, INC.
Subject of the 8-K, entering the settlement agreement and responsible for the £700,000 payment schedule.
- counterpartyREFY Beauty Ltd
Counterparty receiving the settlement payments and granted exclusivity constraints during the exclusivity period.
- subsidiary/partySolésence LLC
Delaware entity that is a named party to the settlement agreement.
